Estimation of Public Health Impact with Use of Nirsevimab During the 2024–2025 RSV Season in the USA: a Modeling Study
Nirsevimab has already achieved substantial reductions in RSV-associated clinical burden at current national coverage levels. Modeled increases in coverage demonstrate large, incremental public health gains with complete universal immunization yielding up to an 86% reduction in RSV MA-LRTDs. These findings highlight the importance of implementing strategies that enhance access, reduce inequities, and support higher, sustained coverage to maximize population-level benefits of RSV prophylaxis.
Authors
- Samira Soudani (ORCID: https://orcid.org/0009-0006-4523-6588)
- Erin N. Hodges (ORCID: https://orcid.org/0000-0001-7298-6356)
- Robert Musci (ORCID: https://orcid.org/0000-0002-6521-6967)
- Jeroen Geurtsen (ORCID: https://orcid.org/0000-0002-8234-846X)
- Maureen P. Neary (ORCID: https://orcid.org/0000-0002-8584-3677)
- Benjamin Yarnoff (ORCID: https://orcid.org/0000-0002-5147-1588)
- Matthieu Beuvelet (ORCID: https://orcid.org/0000-0001-5450-3613)
- Leonard R. Krilov (ORCID: https://orcid.org/0000-0002-2325-5327)
- Vanessa Gabriel (ORCID: https://orcid.org/0000-0002-2058-5160)
- Mehdi Ghemmouri
- Ayman Chit
- Maribel Tribaldos
Institutions
- Ithaka Harbors (US)
- Woodbury University (US)
- University of Toronto (CA)
- Cape Fear Community College (US)
- Morristown Medical Center (US)
- Sanofi (France) (FR)
- Sanofi (Netherlands) (NL)
- C3I (United States) (US)
Publication Details
- Journal
- Pulmonary Therapy
- Published
- 2026-02-26
- DOI
- https://doi.org/10.1007/s41030-026-00348-z
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.00